NMN/NR (Nicotinamide Mononucleotide/Riboside) Cost in Nevada 2026

What Does NMN or NR Actually Cost in Nevada Right Now?

Nevada residents shopping cash-pay for NMN or NR in 2026 will find retail prices centered around $80 per month for a standard 250 to 500 mg daily dose. Prices vary by brand, dose, and whether the product is sold as a capsule or sublingual tablet. Off-the-shelf supplement brands at Nevada pharmacies and online retailers typically range from $50 to $120 monthly depending on dose strength.

Compounded NMN from a Nevada-licensed 503A pharmacy can reduce out-of-pocket cost in some cases, depending on the compounding fee structure your prescribing clinician negotiates. The 503A model requires a valid patient-specific prescription, which is where telehealth providers become relevant for Nevada patients who want supervised access without driving to a clinic.

Neither nicotinamide mononucleotide nor nicotinamide riboside carries an FDA new drug approval at this time. The FDA's position on NMN as a dietary supplement ingredient shifted in 2022 when the agency issued a notification indicating NMN may not lawfully be marketed as a dietary supplement because it was under investigation as a drug, though enforcement has been inconsistent across retailers [1]. Clinicians prescribing NMN through compounding channels operate under a different regulatory pathway than retail supplement sales.

NAD+ (nicotinamide adenine dinucleotide) declines with age in human tissue. Yoshino et al. published data in Science in 2021 (N=25 postmenopausal women with prediabetes) showing that 250 mg/day oral NMN for 10 weeks increased skeletal muscle NAD+ metabolite levels and improved insulin signaling pathways compared to placebo [2]. The sample was small, but the mechanistic findings provided a biological rationale for therapeutic interest that drives prescriber demand in states like Nevada.

A 2022 randomized trial by Yi et al. (N=80) published in GeroScience found that 300 mg/day oral NMN for 60 days produced statistically significant increases in blood NAD+ levels compared to baseline (P<0.001), along with modest improvements in muscle strength and performance measures in older adults [3]. These are not weight-loss or cardiovascular outcome trials, so clinicians interpreting the data should keep the scope of evidence narrow.

Is NMN or NR Covered by Nevada Medicaid?

No. Nevada Medicaid does not cover NMN or NR. Both compounds are classified as dietary supplements or investigational agents rather than FDA-approved drugs with accepted indications, so they fall outside the Medicaid Drug Rebate Program framework entirely [4].

Nevada's Medicaid formulary, administered through the Division of Health Care Financing and Policy, covers drugs with FDA approval and established therapeutic categories. Longevity supplements, NAD precursors, and compounds prescribed off-label for aging-related metabolic support are not reimbursable under the state plan. Patients on Nevada Medicaid who want NMN or NR pay entirely out of pocket.

The federal Medicaid statute at 42 U.S.C. § 1396r-8 defines covered outpatient drugs by reference to FDA-approved labeling [4]. Because NMN has no approved label for any indication, there is no statutory mechanism for coverage. NR (nicotinamide riboside, sold as Tru Niagen and other brands) is similarly sold as a supplement without an approved drug indication, making the same exclusion apply [5].

Some Nevada patients ask whether a compounding prescription changes coverage status. It does not. Compounded drugs are explicitly excluded from Medicaid rebate agreements under the same statute, and state Medicaid programs generally do not cover compounded preparations that lack FDA approval for the compounded indication.

Is Compounded Nicotinamide Mononucleotide Legal in Nevada?

Yes. Compounded NMN is available through Nevada-licensed 503A pharmacies when ordered via a valid patient-specific prescription from a licensed prescriber [6].

Under federal law, Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients based on a valid prescription [6]. Nevada's State Board of Pharmacy enforces these requirements at the state level and licenses compounding pharmacies that meet both federal Current Good Manufacturing Practice standards and Nevada Administrative Code Chapter 639 requirements. A Nevada prescriber, including a telehealth clinician licensed in Nevada, can write a prescription for compounded NMN, and a 503A pharmacy can fill it legally.

The practical implication: patients working with a telehealth provider can receive a compounded NMN prescription at a potentially lower per-milligram cost than branded retail supplements, with the added benefit of dose customization. Typical compounded NMN preparations in Nevada run in capsule or sublingual form at doses from 250 mg to 500 mg per day.

The FDA's 2022 notification letter raised questions about whether NMN could remain on the retail supplement market [1]. That regulatory pressure has driven more clinicians toward the 503A compounding pathway, which operates under a separate legal framework from dietary supplement marketing. Compounding pharmacies are not claiming NMN is a dietary supplement; they are dispensing it as a compounded drug under a prescription, which sidesteps the supplement-marketing restriction.

The HealthRX clinical team uses a three-tier decision framework for Nevada patients asking about NMN access:

1. Patients with no prescriber relationship: direct to telehealth intake, baseline NAD+ metabolomics panel optional, prescription written after clinical review.
2. Patients with existing prescriber but no compounding access: provide 503A pharmacy referral list licensed in Nevada.
3. Patients seeking retail supplement without prescription: confirm no drug interactions (particularly with chemotherapy or PARP inhibitors), document supplement use in chart.

Which Insurance Plans Cover NMN or NR in Nevada?

No commercial insurance plan available in Nevada covers NMN or NR as of 2026. This includes major carriers operating in Nevada's individual and employer markets, such as UnitedHealthcare, Anthem Blue Cross Blue Shield of Nevada, Aetna, and Cigna. None of these carriers list NMN or NR on their formularies because neither compound has an FDA-approved drug indication for any condition [7].

Short answer: insurance does not help here. The reason is straightforward. Insurance formularies cover drugs with approved indications, established safety profiles reviewed by pharmacy and therapeutics committees, and manufacturer rebate agreements. NMN and NR have none of these features under the drug-approval framework. Telehealth visit costs for the prescribing consultation may be covered under some plans' preventive or wellness benefits, but the compound itself is a cash-pay item.

Health savings accounts (HSAs) and flexible spending accounts (FSAs) are worth considering. The IRS has not issued a specific ruling on NMN or NR as HSA-eligible expenses. If prescribed by a licensed clinician for a specific medical condition or metabolic indication documented in the chart, some patients argue successfully that the expense qualifies as a medical care expense under IRC § 213(d). Patients should confirm with their HSA administrator before assuming eligibility.

Nevada does not have a state-level prescription assistance program that covers investigational supplements. The Nevada Department of Health and Human Services' patient assistance resources focus on FDA-approved drugs for chronic disease management [8].

How NAD+ Biology Explains the Clinical Rationale

NAD+ is a coenzyme present in every cell, required for over 500 enzymatic reactions including mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation [9]. Blood and tissue NAD+ concentrations fall by roughly 50% between age 40 and age 60 in humans, a finding replicated across multiple tissue types [10].

NMN and NR are both NAD+ precursors that enter the salvage biosynthesis pathway at different steps. NMN is converted to NAD+ via the enzyme NMNAT. NR is converted first to NMN by NRK enzymes, then to NAD+ [9]. The oral bioavailability of both has been confirmed in human pharmacokinetic studies. Airhart et al. (N=12) showed that a single 1 to 000 mg oral dose of NR raised whole-blood NAD+ by 2.7-fold over 9 hours in healthy adults [11].

Clinicians at academic centers have noted the translation from cellular NAD+ repletion to clinically meaningful patient outcomes remains unproven at scale. The American College of Lifestyle Medicine's 2023 position statement on longevity interventions states: "NAD precursor supplementation demonstrates consistent biochemical activity in human trials; evidence for hard clinical endpoints such as cardiovascular events, cancer incidence, or mortality remains insufficient to support population-level recommendations" [12]. That gap between mechanism and outcome is what keeps NMN off insurance formularies.

A Cochrane-style systematic review published in Nutrients in 2023 (PMID 37513160) reviewed 11 randomized controlled trials of NR or NMN in human subjects and found consistent increases in blood NAD+ across studies but heterogeneous effects on metabolic, cognitive, and physical performance endpoints, with no serious adverse events reported at doses up to 2 to 000 mg/day [13].

Telehealth Access to NMN Prescriptions in Nevada

Nevada permits telehealth prescribing of compounded preparations including NMN. The Nevada Telehealth Act (NRS Chapter 629B) allows licensed providers to establish a valid patient-provider relationship via synchronous audiovisual encounter and to prescribe medications, including compounded drugs, following that encounter [14].

This matters for Nevada patients outside the Las Vegas and Reno metro areas. Rural Nevada counties, including Esmeralda, Mineral, and Lander counties, have minimal specialist access. Telehealth removes the geographic barrier entirely. A Nevada-licensed clinician can conduct an intake visit via video, review labs, and send a compounded NMN prescription to a 503A pharmacy that ships within Nevada.

HealthRX telehealth visits for NAD precursor consultations include a clinical review of the patient's metabolic panel, NAD+ or NMN metabolite labs if ordered, and documented medical justification for the prescription. The consultation fee is a separate cash-pay expense from the compound itself.

The DEA's 2023 telehealth prescribing rules (which focused on controlled substances) do not apply to NMN, as NMN is not a scheduled substance [15]. This means no in-person visit requirement applies before a telehealth prescriber can order compounded NMN in Nevada.

Dosing, Forms, and What Nevada Patients Actually Receive

Standard clinical doses used in published trials range from 250 mg/day to 500 mg/day for NMN and 300 mg/day to 1 to 000 mg/day for NR. Yoshino et al. used 250 mg/day in their 2021 trial [2]. The Yi et al. 2022 trial used 300 mg/day [3]. Higher doses up to 1 to 200 mg/day have been studied without significant adverse effects [13].

Capsule is the most common form in both retail and compounded products. Sublingual formulations have been marketed as having superior bioavailability due to bypassing first-pass hepatic metabolism, but direct comparative pharmacokinetic data between sublingual and oral NMN in humans is limited. Nevada 503A pharmacies most commonly dispense NMN in capsule form; sublingual troches are available on request.

Once-daily dosing in the morning is the standard clinical protocol, consistent with the chronobiology of NAD+ metabolism and circadian sirtuin activity cycles described by Asher and Schibler [16].

Drug interactions to review before starting: NMN may theoretically reduce the efficacy of PARP inhibitors (olaparib, niraparib, rucaparib) by competing for NAD+ substrate, and clinicians should pause NMN 2 weeks before and during PARP inhibitor therapy [17]. No interactions with common antihypertensives, statins, or metformin have been reported in clinical trial populations.

Practical Cost-Reduction Strategies for Nevada Residents

Retail supplement pricing in Nevada ranges from about $50 to $120 per month for NMN or NR. No manufacturer coupon programs for prescription-grade NMN exist through GoodRx or NeedyMeds because those platforms cover FDA-approved drugs, not supplements [18].

The most reliable cost-reduction path is the 503A compounding route. Compounding pharmacies set their own pricing and are not bound by brand-name retail margins. A telehealth consultation that results in a 503A prescription may yield NMN at $40 to $70 per month depending on dose and compounding pharmacy pricing in Nevada.

Buying in bulk (3-month supply) from a retail supplement brand reduces per-day cost by roughly 15% to 20% compared to monthly purchases, based on published pricing from major supplement retailers as of Q1 2026.

Certificate of analysis (COA) verification matters. Retail NMN supplements are not FDA-inspected for potency. An independent analysis by ConsumerLab in 2023 found that several NMN products contained less than 80% of their labeled dose [19]. Compounded 503A preparations are subject to potency testing requirements under USP <797> and <795> standards, offering stronger quality assurance than most retail options [6].

Nevada residents with documented metabolic conditions, such as prediabetes or mitochondrial dysfunction, may have the strongest case for clinical justification of a compounded prescription and potential HSA reimbursement.